Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer
Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) representing ∼85% of new diagnoses. The disease is often detected in an advanced metastatic stage, with poor prognosis and clinical outcome. In order to escape from the primary tumor, cancer...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-02-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fcell.2020.00118/full |
| _version_ | 1818032959815417856 |
|---|---|
| author | Mariana Cooke Martin J. Baker Marcelo G. Kazanietz |
| author_facet | Mariana Cooke Martin J. Baker Marcelo G. Kazanietz |
| author_sort | Mariana Cooke |
| collection | DOAJ |
| description | Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) representing ∼85% of new diagnoses. The disease is often detected in an advanced metastatic stage, with poor prognosis and clinical outcome. In order to escape from the primary tumor, cancer cells acquire highly motile and invasive phenotypes that involve the dynamic reorganization of the actin cytoskeleton. These processes are tightly regulated by Rac1, a small G-protein that participates in the formation of actin-rich membrane protrusions required for cancer cell motility and for the secretion of extracellular matrix (ECM)-degrading proteases. In this perspective article we focus on the mechanisms leading to aberrant Rac1 signaling in NSCLC progression and metastasis, highlighting the role of Rac Guanine nucleotide Exchange Factors (GEFs). A plausible scenario is that specific Rac-GEFs activate discrete intracellular pools of Rac1, leading to unique functional responses in the context of specific oncogenic drivers, such as mutant EGFR or mutant KRAS. The identification of dysregulated Rac signaling regulators may serve to predict critical biomarkers for metastatic disease in lung cancer patients, ultimately aiding in refining patient prognosis and decision-making in the clinical setting. |
| first_indexed | 2024-12-10T06:15:40Z |
| format | Article |
| id | doaj.art-13463fef34554c8c9b24ac7f6cabad88 |
| institution | Directory Open Access Journal |
| issn | 2296-634X |
| language | English |
| last_indexed | 2024-12-10T06:15:40Z |
| publishDate | 2020-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj.art-13463fef34554c8c9b24ac7f6cabad882022-12-22T01:59:27ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2020-02-01810.3389/fcell.2020.00118524350Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung CancerMariana CookeMartin J. BakerMarcelo G. KazanietzLung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) representing ∼85% of new diagnoses. The disease is often detected in an advanced metastatic stage, with poor prognosis and clinical outcome. In order to escape from the primary tumor, cancer cells acquire highly motile and invasive phenotypes that involve the dynamic reorganization of the actin cytoskeleton. These processes are tightly regulated by Rac1, a small G-protein that participates in the formation of actin-rich membrane protrusions required for cancer cell motility and for the secretion of extracellular matrix (ECM)-degrading proteases. In this perspective article we focus on the mechanisms leading to aberrant Rac1 signaling in NSCLC progression and metastasis, highlighting the role of Rac Guanine nucleotide Exchange Factors (GEFs). A plausible scenario is that specific Rac-GEFs activate discrete intracellular pools of Rac1, leading to unique functional responses in the context of specific oncogenic drivers, such as mutant EGFR or mutant KRAS. The identification of dysregulated Rac signaling regulators may serve to predict critical biomarkers for metastatic disease in lung cancer patients, ultimately aiding in refining patient prognosis and decision-making in the clinical setting.https://www.frontiersin.org/article/10.3389/fcell.2020.00118/fullRacRac-GEFlung canceradenocarcinomatumorigenesismetastasis |
| spellingShingle | Mariana Cooke Martin J. Baker Marcelo G. Kazanietz Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer Frontiers in Cell and Developmental Biology Rac Rac-GEF lung cancer adenocarcinoma tumorigenesis metastasis |
| title | Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer |
| title_full | Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer |
| title_fullStr | Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer |
| title_full_unstemmed | Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer |
| title_short | Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer |
| title_sort | rac gef rac signaling and metastatic dissemination in lung cancer |
| topic | Rac Rac-GEF lung cancer adenocarcinoma tumorigenesis metastasis |
| url | https://www.frontiersin.org/article/10.3389/fcell.2020.00118/full |
| work_keys_str_mv | AT marianacooke racgefracsignalingandmetastaticdisseminationinlungcancer AT martinjbaker racgefracsignalingandmetastaticdisseminationinlungcancer AT marcelogkazanietz racgefracsignalingandmetastaticdisseminationinlungcancer |